<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495102</url>
  </required_header>
  <id_info>
    <org_study_id>16877</org_study_id>
    <secondary_id>H9X-MC-GBGL</secondary_id>
    <secondary_id>2017-003490-33</secondary_id>
    <nct_id>NCT03495102</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes</brief_title>
  <acronym>AWARD-11</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of investigational doses of
      once weekly dulaglutide when added to metformin in participants with type 2 diabetes with
      inadequate blood sugar control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c) From Baseline</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The Least Squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included the independent variables:Baseline + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight From Baseline</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with independent variables: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c Target &lt;7.0%</measure>
    <time_frame>Week 36</time_frame>
    <description>Percentage of participants achieving HbA1c target &lt;7.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Glucose (FSG) From Baseline</measure>
    <time_frame>Baseline, Week 36</time_frame>
    <description>Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Documented Symptomatic Hypoglycemic Episodes</measure>
    <time_frame>Week 36</time_frame>
    <description>Hypoglycemia was defined as blood glucose &lt; 54 mg/dL, excluding post-rescue records. Estimate is based on Group Mean from negative binomial model. The negative binomial model for post-baseline comparisons between treatments and control group: Number of episodes = Pooled Country + HbA1c at Baseline (%) + Treatment, with log (exposure in days/365.25) as an offset variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss)</measure>
    <time_frame>Week 4, Week 12, Week 36, Week 52</time_frame>
    <description>Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State</measure>
    <time_frame>Week 4, Week 12, Week 36, Week 52</time_frame>
    <description>Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1842</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dulaglutide 1.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dulaglutide 3 mg administered SC once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide 4.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dulaglutide 4.5 mg administered SC once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide 1.5 mg</arm_group_label>
    <arm_group_label>Dulaglutide 3 mg</arm_group_label>
    <arm_group_label>Dulaglutide 4.5 mg</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have type 2 diabetes mellitus (T2DM) for at least 6 months

          -  Have been treated with stable metformin dose for at least 3 months

          -  Have HbA1c ≥7.5% and ≤11.0% at study entry

          -  Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m^2)

        Exclusion Criteria:

          -  Have type 1 diabetes mellitus

          -  Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not
             including prior short term insulin use (≤14 days)

          -  Have been taking any other medicine for diabetes (other than metformin) during the
             last 3 months

          -  Have used in the last 3 months (or plan to use) prescription weight loss medications

          -  Have disorders associated with slowed emptying of the stomach contents, or have had
             any stomach surgeries for the purpose of weight loss

          -  Current participation in or intent to begin during the study an organized diet and/or
             exercise weight reduction program (other than the lifestyle and dietary measures for
             diabetes)

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease other
             than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level
             &gt;2.5 times the upper limit of the reference range, as determined by the central
             laboratory at study entry; participants with NAFLD are eligible for participation in
             this trial

          -  Had chronic or acute pancreatitis any time prior to study entry

          -  Have had a heart attack or stroke in the past 2 months, or have heart failure that
             significantly limits their physical activity

          -  Estimated glomerular filtration rate (eGFR) &lt;30 milliliters/minute/1.73m^2 (or lower
             than the country-specific threshold for discontinuing metformin therapy per local
             label), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as
             determined by the central laboratory at study entry and confirmed at lead-in

          -  Have a personal or family history of medullary thyroid carcinoma or personal history
             of multiple endocrine neoplasia syndrome type 2

          -  Have proliferative retinopathy or maculopathy requiring acute treatment according to
             the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus- Chandler</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus/Central Arizona Medical Associates, PC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Phoenix Med Clinic LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Trials, Inc.</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Clinical Research</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Access Research</name>
      <address>
        <city>Santa Clarita</city>
        <state>California</state>
        <zip>91321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Investigators, Inc.</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALL Medical Research, LLC</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oviedo Medical Research</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urban Family Practice Associates, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>In-Quest Medical Research, LLC- Peachtree Corners</name>
      <address>
        <city>Peachtree Corners</city>
        <state>Georgia</state>
        <zip>30071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East West Medical Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials LLLP</name>
      <address>
        <city>Blackfoot</city>
        <state>Idaho</state>
        <zip>83221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saltzer Medical Group. P.A.</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus/Clinical Research Advantage</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iderc, P.L.C.</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InterMed, PA</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NECCR PrimaCare Research, LLC</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aa Mrc Llc</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Troy Internal Medicine, PC</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research, LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Health Research</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Institute</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Internal Medicine, P.A.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrinology Consultants PC</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intend Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Corvallis Clinic P.C.</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network Inc</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Valley Medical Group, Inc.</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detweiler Family Medicine</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sudir Bansal M.D. Inc.</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston, LLC</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Research and Medicine (CHARM)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Endocrinology and Associates PA</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consano Clinical Research</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Diagnostic Clinic</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPoint Trials, LLC</name>
      <address>
        <city>Waxahachie</city>
        <state>Texas</state>
        <zip>75165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Clincial Research Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walla Walla Clinic</name>
      <address>
        <city>Walla Walla</city>
        <state>Washington</state>
        <zip>99362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital &amp; Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prevea Clinic, Inc</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico CICEMO</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDIC-Centro de Investigaciones Clinicas</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Medicas IMOBA S.R.L.</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Metabólicas (CINME)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y Prevencion Cardiovascular (CIPREC)</name>
      <address>
        <city>Ciudad Autonoma de</city>
        <state>Buenos Aires</state>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIPADI</name>
      <address>
        <city>Godoy Cruz</city>
        <state>Mendoza</state>
        <zip>M5501ARP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AXISMED SRL - Bioclinica Research Network</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1430CKE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENUDIAB</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>1408</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Viamonte</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Centenario</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1204AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cemediab - Centro Médico Diabetológico Dr. Alejandro Chertkoff</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1205AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mautalen Salud e Investigación - Servicio de Endocrinología</name>
      <address>
        <city>Ciudad Autonoma De Buenos Air</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Strusberg</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000EDC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado San Vicente Diabetes</name>
      <address>
        <city>Cordoba</city>
        <zip>X5006CBI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC</name>
      <address>
        <city>Cordoba</city>
        <zip>X5008HHW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Korneuburg-Stockerau, Standort Stockerau</name>
      <address>
        <city>Stockerau</city>
        <state>Niederösterreich</state>
        <zip>2000</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Evelyn Fließer-Görzer</name>
      <address>
        <city>Saint Stefan Ob Stainz</city>
        <state>Steiermark</state>
        <zip>8511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIVIT Institut am LKH Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KA Rudolfstiftung</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für klinische Studien Dr. Ursula Hanusch GmbH</name>
      <address>
        <city>Wien</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bailey Clinic</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N 6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aggarwal and Associates Ltd</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T. Nemtean Medicine Professional Corporation</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4Y 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluewater Clinical Research Group Inc</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stayner Medical Clinic</name>
      <address>
        <city>Stayner</city>
        <state>Ontario</state>
        <zip>L0M 1S0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anil K. Gupta Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatriko Palaiou Falirou, Medical Center</name>
      <address>
        <city>Palaio Faliro</city>
        <state>Athens</state>
        <zip>17562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Ampelokipoi</city>
        <state>Attica</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gen Hospital of Athens G Gennimatas</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.Papanikolaou General Hospital</name>
      <address>
        <city>Exohi</city>
        <state>Thessaloniki</state>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thermi Clinic</name>
      <address>
        <city>Thermi</city>
        <state>Thessaloniki</state>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens Euroclinic</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHEPA Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ippokrateio General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54639</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromedica - General Clinic of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studium Egeszseghaz Kft.</name>
      <address>
        <city>Kalocsa</city>
        <state>Bacs-Kiskun</state>
        <zip>6300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Gyula Korhaz es Rendelointezet</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdu-Bihar</state>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grof Esterhazy Korhaz es Rendelointezeti Szakrendelo</name>
      <address>
        <city>Papa</city>
        <state>Veszprem</state>
        <zip>8500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Margit Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinDiab Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strazsahegy Medicina Bt.</name>
      <address>
        <city>Budapest</city>
        <zip>1171</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRANTOR 99 Bt.</name>
      <address>
        <city>Budapest</city>
        <zip>1213</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanizsai Dorottya Korhaz</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Korhaz</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maccabi Diabetes Clinic, Grand Canyon, North District, Haifa</name>
      <address>
        <city>Haifa</city>
        <zip>3299001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linn Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3515209</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>911201</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clalit Health Services - Shuali Clinic</name>
      <address>
        <city>Raanana</city>
        <zip>4345204</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZIV Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakhnin Community Clinic, Clalit Health Services</name>
      <address>
        <city>Sakhnin</city>
        <zip>3081000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv Jaffa</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Medical Center (DMC)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6148002</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Florence</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Senese Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Universitaria degli Studi G D'Annunzio</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Goretti</name>
      <address>
        <city>Latina</city>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Maggiore Borgo Trento</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion en Salud y Metabolismo S.C</name>
      <address>
        <city>Chihuahua</city>
        <zip>31217</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ ZDROWIE Osteo-Medic</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradnia Diabetologiczna SN ZOZ Lege Artis</name>
      <address>
        <city>Bialystok</city>
        <zip>15-404</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NS ZOZ Osrodek Diabetologiczny &quot; Popula&quot;</name>
      <address>
        <city>Bialystok</city>
        <zip>15-445</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych, PI House</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Salvia s.c.</name>
      <address>
        <city>Katowice</city>
        <zip>40-772</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Diab-Endo-Met</name>
      <address>
        <city>Krakow</city>
        <zip>31-261</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinety Terpa</name>
      <address>
        <city>Lublin</city>
        <zip>20-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Specjalistyczna MEDICA</name>
      <address>
        <city>Lublin</city>
        <zip>20-538</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne OMEDICA</name>
      <address>
        <city>Poznan</city>
        <zip>60-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praktyka Lekarska</name>
      <address>
        <city>Poznan</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Neuro - Kard</name>
      <address>
        <city>Poznan</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek</name>
      <address>
        <city>Ruda Slaska</city>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSW</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalna Poradnia Diabetologiczna</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Cardiovascular Corp.</name>
      <address>
        <city>Ponce</city>
        <zip>00717</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group PSC</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office: Dr. Luis Rivera Colon</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. C. Grandmed S.R.L., Str.</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <zip>410159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Gama Diamed SRL</name>
      <address>
        <city>Mangalia</city>
        <state>Constanta</state>
        <zip>905500</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta Satu Mare</name>
      <address>
        <city>Satu-Mare</city>
        <state>Jud Satu-Mare</state>
        <zip>440055</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMI DNBM Dr. Pop Lavinia</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramures</state>
        <zip>430222</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosamext SRL</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures</state>
        <zip>540098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Diabmed Dr Popescu Alexandrina SRL</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <zip>100163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Dianutrilife Medica SRL</name>
      <address>
        <city>Ploiesti</city>
        <state>Prahova</state>
        <zip>100561</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Dr. Negrisanu</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300456</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinetul Medical Nicodiab SRL</name>
      <address>
        <city>Bucharest</city>
        <zip>010507</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Easydiet SRL</name>
      <address>
        <city>Bucuresti</city>
        <zip>010627</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Nutrilife SRL</name>
      <address>
        <city>Bucuresti</city>
        <zip>013682</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Medcon SRL</name>
      <address>
        <city>Buzau</city>
        <zip>120203</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Unirea SRL</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical Urodiamed S.R.L.</name>
      <address>
        <city>Craiova</city>
        <zip>200349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milena Sante SRL</name>
      <address>
        <city>Galati</city>
        <zip>800001</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Olimpia Med SRL</name>
      <address>
        <city>Iasi</city>
        <zip>700400</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Hospital</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk the first city clinical hospital</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital of Saint Martyr Elizabeth</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb GUZ &quot;Diagnostic Center #85&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Human care s.r.o.</name>
      <address>
        <city>Kosice</city>
        <state>Slovak Republic</state>
        <zip>04012</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediVet s.r.o.</name>
      <address>
        <city>Malacky</city>
        <state>Slovak Republic</state>
        <zip>90101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Areteus s.r.o.</name>
      <address>
        <city>Trebisov</city>
        <state>Slovak Republic</state>
        <zip>07501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diacrin s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>84102</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noemis, s.r.o.</name>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <zip>91501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FUNKYSTUFF s.r.o.</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Jan Culak, s.r.o.</name>
      <address>
        <city>Prievidza</city>
        <zip>97101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIA-MED CENTRUM s.r.o.</name>
      <address>
        <city>Puchov</city>
        <zip>02001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tatratrial s.r.o.</name>
      <address>
        <city>Roznava</city>
        <zip>04801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques De Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Juaneda</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron Madrid</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ciencias medicas</name>
      <address>
        <city>Alicante</city>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica San Pedro</name>
      <address>
        <city>Almeria</city>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Medico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Especialidades San Jose Obrero (Barbarela)</name>
      <address>
        <city>Malaga</city>
        <zip>29006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Nuevas Tecnologias en Diabetes y Endocrinologia</name>
      <address>
        <city>Seville</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinica Galileo</name>
      <address>
        <city>Teruel</city>
        <zip>44002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705, ROC</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Center</name>
      <address>
        <city>Tainan City</city>
        <zip>71004</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/adult-type-2-diabetes/GBGL#?postal=</url>
    <description>A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes (AWARD-11)</description>
  </link>
  <verification_date>December 15, 2019</verification_date>
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <results_first_submitted>May 28, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2020</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03495102/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03495102/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dulaglutide 1.5 mg</title>
          <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
        </group>
        <group group_id="P2">
          <title>Dulaglutide 3 mg</title>
          <description>Dulaglutide 3 mg administered SC once a week.</description>
        </group>
        <group group_id="P3">
          <title>Dulaglutide 4.5 mg</title>
          <description>Dulaglutide 4.5 mg administered SC once a week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
                <participants group_id="P2" count="616"/>
                <participants group_id="P3" count="614"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
                <participants group_id="P2" count="616"/>
                <participants group_id="P3" count="614"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="556"/>
                <participants group_id="P2" count="549"/>
                <participants group_id="P3" count="560"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Duplicated at Another Site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Primary Care Physician Recommendation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated to Another Country</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant was in Rehabilitation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Dulaglutide 1.5 mg</title>
          <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
        </group>
        <group group_id="B2">
          <title>Dulaglutide 3 mg</title>
          <description>Dulaglutide 3 mg administered SC once a week.</description>
        </group>
        <group group_id="B3">
          <title>Dulaglutide 4.5 mg</title>
          <description>Dulaglutide 4.5 mg administered SC once a week.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="612"/>
            <count group_id="B2" value="616"/>
            <count group_id="B3" value="614"/>
            <count group_id="B4" value="1842"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="9.7"/>
                    <measurement group_id="B2" value="56.9" spread="10.2"/>
                    <measurement group_id="B3" value="56.6" spread="10.2"/>
                    <measurement group_id="B4" value="57.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="296"/>
                    <measurement group_id="B4" value="898"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="318"/>
                    <measurement group_id="B4" value="944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="641"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="363"/>
                    <measurement group_id="B3" value="371"/>
                    <measurement group_id="B4" value="1103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="529"/>
                    <measurement group_id="B2" value="521"/>
                    <measurement group_id="B3" value="530"/>
                    <measurement group_id="B4" value="1580"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C (HbA1c) at Baseline</title>
          <description>HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.</description>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.64" spread="0.94"/>
                    <measurement group_id="B2" value="8.63" spread="1.00"/>
                    <measurement group_id="B3" value="8.64" spread="0.91"/>
                    <measurement group_id="B4" value="8.64" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin A1c (HbA1c) From Baseline</title>
        <description>HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The Least Squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included the independent variables:Baseline + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline HbA1c value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c (HbA1c) From Baseline</title>
          <description>HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The Least Squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included the independent variables:Baseline + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
          <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline HbA1c value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
          <units>Percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="521"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="0.04"/>
                    <measurement group_id="O2" value="-1.71" spread="0.04"/>
                    <measurement group_id="O3" value="-1.87" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight From Baseline</title>
        <description>Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with independent variables: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline body weight value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight From Baseline</title>
          <description>Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with independent variables: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
          <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline body weight value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
          <units>Kilograms (Kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="520"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="0.19"/>
                    <measurement group_id="O2" value="-4.0" spread="0.19"/>
                    <measurement group_id="O3" value="-4.7" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving HbA1c Target &lt;7.0%</title>
        <description>Percentage of participants achieving HbA1c target &lt;7.0%.</description>
        <time_frame>Week 36</time_frame>
        <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline HbA1c value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HbA1c Target &lt;7.0%</title>
          <description>Percentage of participants achieving HbA1c target &lt;7.0%.</description>
          <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline HbA1c value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="521"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.98"/>
                    <measurement group_id="O2" value="64.68"/>
                    <measurement group_id="O3" value="71.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Glucose (FSG) From Baseline</title>
        <description>Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
        <time_frame>Baseline, Week 36</time_frame>
        <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline FSG value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Glucose (FSG) From Baseline</title>
          <description>Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares).</description>
          <population>All participants who received at least one dose of study drug and had a baseline and at least 1 post-baseline FSG value, excluding data post treatment discontinuation and/or initiation of new antihyperglycemic medications.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="509"/>
                <count group_id="O3" value="514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.2" spread="1.50"/>
                    <measurement group_id="O2" value="-47.9" spread="1.50"/>
                    <measurement group_id="O3" value="-52.3" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.8</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.3</ci_lower_limit>
            <ci_upper_limit>-3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Documented Symptomatic Hypoglycemic Episodes</title>
        <description>Hypoglycemia was defined as blood glucose &lt; 54 mg/dL, excluding post-rescue records. Estimate is based on Group Mean from negative binomial model. The negative binomial model for post-baseline comparisons between treatments and control group: Number of episodes = Pooled Country + HbA1c at Baseline (%) + Treatment, with log (exposure in days/365.25) as an offset variable.</description>
        <time_frame>Week 36</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Documented Symptomatic Hypoglycemic Episodes</title>
          <description>Hypoglycemia was defined as blood glucose &lt; 54 mg/dL, excluding post-rescue records. Estimate is based on Group Mean from negative binomial model. The negative binomial model for post-baseline comparisons between treatments and control group: Number of episodes = Pooled Country + HbA1c at Baseline (%) + Treatment, with log (exposure in days/365.25) as an offset variable.</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>Episodes/participant/365.25 days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.01"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.02" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss)</title>
        <description>Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss).</description>
        <time_frame>Week 4, Week 12, Week 36, Week 52</time_frame>
        <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss)</title>
          <description>Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss).</description>
          <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="77.7" upper_limit="81.7"/>
                    <measurement group_id="O2" value="159" lower_limit="155" upper_limit="163"/>
                    <measurement group_id="O3" value="238" lower_limit="232" upper_limit="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State</title>
        <description>Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State.</description>
        <time_frame>Week 4, Week 12, Week 36, Week 52</time_frame>
        <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dulaglutide 1.5 mg</title>
            <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide 3 mg</title>
            <description>Dulaglutide 3 mg administered SC once a week.</description>
          </group>
          <group group_id="O3">
            <title>Dulaglutide 4.5 mg</title>
            <description>Dulaglutide 4.5 mg administered SC once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State</title>
          <description>Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State.</description>
          <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram*hour/milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="616"/>
                <count group_id="O3" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11200" lower_limit="10900" upper_limit="11500"/>
                    <measurement group_id="O2" value="22300" lower_limit="21800" upper_limit="22900"/>
                    <measurement group_id="O3" value="33400" lower_limit="32700" upper_limit="34200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 56</time_frame>
      <desc>All participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dulaglutide 1.5 mg</title>
          <description>Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.</description>
        </group>
        <group group_id="E2">
          <title>Dulaglutide 3 mg</title>
          <description>Dulaglutide 3 mg administered SC once a week.</description>
        </group>
        <group group_id="E3">
          <title>Dulaglutide 4.5 mg</title>
          <description>Dulaglutide 4.5 mg administered SC once a week.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="616"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="616"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Medical device site joint inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>West nile viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Ecg signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Electrocardiogram t wave inversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Osteoarthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Metastatic uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Diabetic mononeuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="296"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="296"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hypersensitivity pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="612"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="612"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="616"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="616"/>
                <counts group_id="E3" subjects_affected="195" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="83" subjects_affected="48" subjects_at_risk="612"/>
                <counts group_id="E2" events="118" subjects_affected="75" subjects_at_risk="616"/>
                <counts group_id="E3" events="176" subjects_affected="70" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="612"/>
                <counts group_id="E2" events="56" subjects_affected="33" subjects_at_risk="616"/>
                <counts group_id="E3" events="35" subjects_affected="18" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="121" subjects_affected="87" subjects_at_risk="612"/>
                <counts group_id="E2" events="180" subjects_affected="99" subjects_at_risk="616"/>
                <counts group_id="E3" events="192" subjects_affected="106" subjects_at_risk="614"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="63" subjects_affected="40" subjects_at_risk="612"/>
                <counts group_id="E2" events="89" subjects_affected="57" subjects_at_risk="616"/>
                <counts group_id="E3" events="108" subjects_affected="64" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="612"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="616"/>
                <counts group_id="E3" events="48" subjects_affected="39" subjects_at_risk="614"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

